Locoregional therapies using slow-release conjugates
Slow-release conjugates using hydrogels and aluminum hydroxide particles address the challenge of short local residence time, achieving enhanced therapeutic efficacy and reduced systemic toxicities by controlled release of therapeutic agents.
WO2025174913A1 Publication Date: 2025-08-21PROLYNX LLC
3 Cites 2 Cited by
Patent Information
- Application Number
- PCT/US2025/015638
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-02-12
- Filing Date
- 2025-02-12
- Publication Date
- 2025-08-21
AI Technical Summary
Technical Problem
Existing therapeutic agents face challenges with short local residence time in target tissues, leading to undesired systemic toxicities and limited efficacy due to poor transport, systemic clearance, and uncontrolled release mechanisms.
Method used
Development of slow-release conjugates using insoluble carriers like hydrogels and aluminum hydroxide particles for locoregional administration, allowing controlled and extended release of therapeutic agents such as antibodies and ADCs, minimizing systemic concentrations and enhancing local efficacy.
Benefits of technology
The slow-release conjugates provide sustained high local concentrations of therapeutic agents, reducing systemic toxicities and improving treatment efficacy in conditions like cancer and autoimmune disorders.
✦ Generated by Eureka AI based on patent content.
Abstract
Provided herein are locoregional therapies using conjugates of therapeutic agents that demonstrate extended release of the native therapeutic agents, as well as methods for the manufacture of such conjugates. These conjugates may be useful in the treatment of various conditions and diseases that respond to the extended exposure to the therapeutic agents, or for delivery of therapeutic agents that suffer from undesired systemic toxicities. In certain embodiments, the locoregional therapy is intratumoral therapy, which may be combined with a systemic or local therapy for enhanced therapeutic efficacy and reduced toxicity of the combined agents.
Need to check novelty before this filing date? Find Prior Art